Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism

被引:116
作者
Granfors, MT [1 ]
Backman, JT [1 ]
Neuvonen, M [1 ]
Neuvonen, PJ [1 ]
机构
[1] Univ Helsinki, Dept Clin Pharmacol, FIN-00290 Helsinki, Finland
关键词
D O I
10.1016/j.clpt.2004.08.018
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Background and Objective: Tizanidine, a centrally acting skeletal muscle relaxant, is metabolized mainly by cytochrome P450 (CYP) 1A2 and has a low oral bioavailability. The fluoroquinolone antibiotic ciprofloxacin is only a moderately potent inhibitor of CYP1A2. Our objective was to study the extent and mechanism of a possible interaction of ciprofloxacin with tizanidine. Methods: In a double-blind, randomized, 2-phase crossover study, 10 healthy volunteers ingested 500 mg ciprofloxacin or placebo twice daily for 3 days. On day 3, a single dose of 4 mg tizanidine was ingested 1 hour after the morning dose of ciprofloxacin. Plasma concentrations of tizanidine and ciprofloxacin and pharmacodynamic variables were measured. A caffeine test was used as a marker for CYP1A2 activity. Results: Ciprofloxacin increased the area under the plasma concentration-time curve from time 0 to infinity [AUC(O-infinity)] of tizanidine by 10-fold (range, 6-fold to 24-fold; P < .001) and its peak concentration by 7-fold (range, 4-fold to 21-fold; P < .001), whereas its elimination half-life was only prolonged from 1.5 to 1.8 hours (P = .007). The pharmacodynamic effects of tizanidine were much stronger during the ciprofloxacin phase than during the placebo phase with regard to changes in systolic blood pressure (-35 mm Hg versus -15 mm Hg, P = .001), diastolic blood pressure (-24 mm Hg versus -11 mm Hg, P < .001), Digit Symbol Substitution Test (P = .02), subjective drug effect (P = .002), and subjective drowsiness (P = .009). The AUC(O-infinity) of tizanidine and its change correlated (P < .01) with the caffeine/paraxanthine ratio and its change. Conclusions: Ciprofloxacin greatly elevates plasma concentrations of tizanidine and dangerously potentiates its hypotensive and sedative effects, mainly by inhibiting its CYP1A2-mediated metabolism, at least when administered I hour before tizanidine. Tizanidine seems to be a useful probe drug for measuring presystemic metabolism by CYP1A-2. Care should be exercised when tizanidine is used concomitantly with ciprofloxacin.
引用
收藏
页码:598 / 606
页数:9
相关论文
共 26 条
[1]
Rifampin drastically reduces plasma concentrations and effects of oral midazolam [J].
Backman, JT ;
Olkkola, KT ;
Neuvonen, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (01) :7-13
[2]
THE EFFECT OF CIPROFLOXACIN ON THEOPHYLLINE PHARMACOKINETICS IN HEALTHY-SUBJECTS [J].
BATTY, KT ;
DAVIS, TME ;
ILETT, KF ;
DUSCI, LJ ;
LANGTON, SR .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 39 (03) :305-311
[3]
Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions [J].
Bertz, RJ ;
Granneman, GR .
CLINICAL PHARMACOKINETICS, 1997, 32 (03) :210-258
[4]
Ciprofloxacin - An updated review of its pharmacology, therapeutic efficacy and tolerability [J].
Davis, R ;
Markham, A ;
Balfour, JA .
DRUGS, 1996, 51 (06) :1019-1074
[5]
Human extrahepatic cytochromes P450: Function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts [J].
Ding, XX ;
Kaminsky, LS .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2003, 43 :149-173
[6]
DOLLERY C, 1999, THERAPEUTIC DRUGS, pC4
[7]
DOLLERY C, 1999, THERAPEUTIC DRUGS, pC230
[8]
Evaluation of caffeine as a test drug for CYPIA2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations [J].
Fuhr, U ;
Rost, KL ;
Engelhardt, R ;
Sachs, M ;
Liermann, D ;
Belloc, C ;
Beaune, P ;
Janezic, S ;
Grant, D ;
Meyer, UA ;
Staib, AH .
PHARMACOGENETICS, 1996, 6 (02) :159-176
[9]
Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro [J].
Granfors, MT ;
Backman, JT ;
Laitila, J ;
Neuvonen, PJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (03) :349-353
[10]
Fluvoxamine drastically increases concentrations and effects of tizanidine: A potentially hazardous interaction [J].
Granfors, MT ;
Backman, JT ;
Neuvonen, M ;
Ahonen, J ;
Neuvonen, PJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (04) :331-341